+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 27 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness of delgocitinib cream 20 mgg applied twice daily compared to a non-active cream vehicle in treating adults with mild to severe palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This phase 2a, double-blind study aims to provide proof-of-concept evidence over a 16-week treatment period. Participants will be randomly assigned to one of two groups one group will apply delgocitinib cream twice daily, and the other will apply a matching vehicle cream twice daily for 16 weeks. The study includes approximately 9 visits over about 18 weeks in total, covering treatment and follow-up periods. Throughout the trial, participants will attend scheduled visits for assessments including skin evaluations, photography confirmation of PPP, and various symptom and quality of life measures. Researchers will monitor improvements using the PPP Area and Severity Index PPPASI and Physician Global Assessment PGA, as well as track adverse events and changes in symptoms like itch and pain. The main outcome is the number of participants achieving at least a 75% improvement in PPPASI score after 16 weeks of treatment.

Age: 18Years +All GendersPhase 2
40 locations
S

Actively Recruiting

Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.

Age: 18Years +All GendersPhase 3
33 locations
S

Actively Recruiting

Researchers are evaluating the effects of NB-4746 compared with placebo in adults with amyotrophic lateral sclerosis ALS. This trial aims to understand the safety, side effects, how NB-4746 moves through the body, and changes in a blood marker called neurofilament light NfL, which indicates nerve cell damage. The study is divided into two parts and includes an optional open-label extension. In Part A, participants are randomly assigned to receive either a low dose of NB-4746, a high dose of NB-4746, or placebo capsules taken twice daily for about one month. In Part B, participants are again randomized to receive NB-4746 at a dose determined based on Part A results or placebo capsules twice daily for about twelve weeks. After completing Part A or B, participants may opt to continue treatment in an open-label extension lasting up to one year. Participants will be monitored throughout the trial with regular health checks focusing on ALS symptoms and overall wellbeing. Researchers will track adverse events, measure blood levels of NB-4746, and assess changes in neurofilament light to evaluate nerve damage. Safety and tolerability will be evaluated from enrollment through the treatment periods, with ongoing monitoring during the extension phase.

Age: 18Years - 80YearsAll GendersPhase 1Phase 2
12 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis who have already completed treatment in a prior APG777 study. The study is a multicenter, double-blind, phase 2 extension designed for participants who, according to the investigator, could benefit from continued APG777 treatment. The study consists of three periods a Screening Visit coinciding with the last visit of the parent studys Maintenance Period an Extended Treatment Period where participants maintain their APG777 dose from the previous study or receive open-label APG777 if they did not meet certain response criteria and a Post-treatment Follow-up Period. Participants receive APG777 as subcutaneous injections every 12 or 24 weeks, depending on their previous dosing regimen or study arm assignment. During the study, participants will have assessments for safety and efficacy, including monitoring treatment-emergent adverse events for up to 3 years. Researchers will also track improvements in eczema severity, itch symptoms, use of rescue therapy, and serum drug concentrations over an average of 2 years during the Extended Treatment Period. Participation may last up to 3 years, including follow-up to observe long-term outcomes.

Age: 18Years +All GendersPhase 2
80 locations
B

Actively Recruiting

Researchers are conducting the BALANCE platform trial to study different treatment strategies for Gram-negative bloodstream infections GN BSIs. This adaptive trial addresses important questions about managing these infections, which have high risks and are complicated by increasing antibiotic resistance. The trial builds on previous research and aims to improve treatment approaches and patient outcomes while addressing antimicrobial resistance challenges. Participants in the trial receive various treatments depending on the domain they are assigned to. These include strategies such as antibiotic de-escalation or continuation, use of oral beta-lactams versus non-beta-lactams, decisions about replacing or retaining central vascular catheters, comparison of cephalosporins versus carbapenems for certain bacteria, and whether to perform routine follow-up blood cultures. The trial is open-label and embedded in routine hospital care, with an adaptive design that allows adding or removing treatment domains over time. During the study, participants undergo regular evaluations including monitoring for death, reinfection, readmission, and development of antimicrobial resistance over 90 days. The main measurement used is the Desirability of Outcome Ranking DOOR scale. Interim analyses occur frequently to assess results and determine continuation. Participation includes hospital admission, treatment under routine care with study interventions, and follow-up for outcome assessments. The study is planned to continue until April 2028 and enrolls patients from newborns to elderly adults.

Age: 0Years - 130YearsAll GendersPhase Not Applicable
39 locations
G

Actively Recruiting

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Age: 12Years +All Genders
116 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of bimekizumab compared to a placebo in adults with palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This Phase 3 study aims to provide important information about this treatment option in participants who have had PPP for at least 24 weeks and meet specific severity criteria. Participants will be randomly assigned to one of two groups one receiving bimekizumab throughout the study and the other receiving a placebo initially, then switching to bimekizumab during the maintenance phase. The treatments are given at scheduled times, and the study includes an open-label extension period to further assess the treatment. During the study, participants will have regular assessments of their skin condition, including the Palmoplantar Pustulosis-Investigator Global Assessment and Palmoplantar Pustulosis Area Severity Index at weeks 8 and 16. Quality of life and pain levels will also be evaluated. Safety is closely monitored through the recording of any adverse events up to approximately 117 weeks. The total time commitment includes initial treatment and an extended safety follow-up period.

Age: 18Years +All GendersPhase 3
91 locations
E

Actively Recruiting

Researchers are evaluating whether a combination of elranatamab, daratumumab, and lenalidomide provides better clinical benefits compared to a combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in people newly diagnosed with multiple myeloma who cannot have a transplant. This phase 3 study includes two parts the first focuses on safety, tolerability, and dose finding for elranatamab combinations, while the second compares treatment effectiveness and progression outcomes between the two combination therapies. Participants receive different drug combinations depending on the study part and assigned group. Part 1 evaluates elranatamab combined with daratumumab and lenalidomide or elranatamab with lenalidomide alone, focusing on dose levels. Part 2 randomly assigns participants to receive either elranatamab with daratumumab and lenalidomide or the comparator regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone. During the study, participants undergo regular assessments to monitor safety, treatment response, and disease progression, including measuring minimal residual disease negative complete response and progression-free survival. Researchers also track overall survival, adverse events, lab results, drug pharmacokinetics, and quality of life over an extended follow-up lasting up to approximately eight years after randomization.

Age: 18Years +All GendersPhase 3
180 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety and effectiveness of ORKA-001 in adults who have moderate-to-severe plaque psoriasis and previously took part in an Oruka Therapeutics study. It is an open-label extension study where all participants receive the study drug to monitor ongoing treatment effects and safety over an extended period. Participants will receive ORKA-001 as a subcutaneous injection through different dosing schedules once a year high or low dose, twice a year, or no drug until meeting specific response criteria. The treatment period can last up to about 96 weeks, followed by a post-treatment follow-up lasting approximately 48 weeks after the last study visit. During the study, participants will undergo safety monitoring, including checking for adverse events. Effectiveness will be assessed by measuring skin condition improvements using tools like the Psoriasis Area and Severity Index PASI and Investigators Global Assessment IGA. The team will track these results over time to understand how participants maintain their skin improvements and overall treatment tolerance.

Age: 18Years +All GendersPhase 2
39 locations
C

Actively Recruiting

Researchers are studying Canadian cancer patients who have rare genetic changes in their tumors, such as alterations in genes like ALK, EGFR, ROS1, BRAF, and KRAS G12C. These rare molecular alterations can affect how the cancer responds to certain targeted drugs called tyrosine kinase inhibitors TKIs. The study aims to better understand the natural history of these cancers and compare treatment outcomes, including side effects and patient-reported experiences, across different therapies. The study observes cancer patients who have received or are currently receiving TKIs or other targeted therapies. It includes three groups living patients with confirmed rare molecular alterations, deceased patients with such alterations, and a comparator group of cancer patients without these rare changes. Patient-reported outcomes are collected through surveys at baseline and every three months, especially when treatments change. Participants provide molecular testing reports and complete quality of life questionnaires regularly for up to 10 years. Researchers track progression-free survival or overall survival, the development of brain metastases, and economic impacts related to treatment. The study collects data from medical records and patient surveys to understand treatment patterns, effectiveness, and quality of life in the real-world Canadian context.

Age: 18Years +All Genders
27 locations

1-10 of 27

1